Davenport & Co’s Cognition Therapeutics CGTX Stock Holding History

Davenport & Co’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.9M	Buy	4,259,511 +1,366,703	+47%	+$1.62M	0.02%	374
2026 Q1	$2.2M	Buy	2,892,808 +20,972	+0.7%	+$24.4K	0.01%	506
2025 Q4	$3.88M	Buy	2,871,836 +182,500	+7%	+$296K	0.02%	395
2025 Q3	$3.63M	Buy	+2,689,336	New	+$3.67M	0.02%	404

Other funds holding CGTX

EWM

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

BSB

Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

BIA

Barry Investment Advisors New Bedford, Massachusetts $478M AUM 23.65% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

Davenport & Co's CGTX Position: Q2 2026 in Review

Davenport & Co increased its Cognition Therapeutics (CGTX) stake by 47% in Q2 2026, buying an estimated $1.62M and bringing the position to 4,259,511 shares worth $4.9M. The position accounts for 0.02% of the portfolio, ranked #374.

Davenport & Co first reported a position in CGTX in Q3 2025 and has held it in 4 quarters since. 6 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

Davenport & Co held 4,259,511 shares of Cognition Therapeutics worth $4.9M as of Q2 2026.
Davenport & Co bought 1,366,703 Cognition Therapeutics shares in Q2 2026, an estimated $1.62M.
Cognition Therapeutics made up 0.02% of Davenport & Co's portfolio in Q2 2026, its #374 holding.
Davenport & Co first reported a position in Cognition Therapeutics in Q3 2025 and has held it in 4 quarters since.
6 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.